
    
      This is a phase 3, multicenter, double-blind, randomized, placebo-controlled study of IBI306
      in Chinese non-familiar hypercholesterolemia Subjects with very high or high cardiovascular
      risk. A total of 600 subjects who meet admission criteria will be randomized and receive one
      of the 3 dose levels of IBI306 or matching placebo: 450mg Q4W, 600mg Q6W or 600mg Q8W. The
      double blind period for the 450mg Q4W and 600mg Q6W groups will be 12 weeks, and for the
      600mg Q8W groups will be 16weeks. The study will last 52 weeks
    
  